EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Post‐surgery level of circulating DNA in stage III colon cancer patients: Impact on the reliability of minimal residual disease detection

Andrei Kudriavtsev iD, Saidi Daoud, Catalina Isabel Cofre Muñoz, Alexia Mirandola, Ekaterina Pisareva, Javier Gonzalo Ruiz, Marco Macagno, Nadia Saoudi Gonzalez, Evelyne Crapez, Marc Ychou, Ramon Salazar Soler, Elisabetta Fenocchio und 6 weitere

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70370 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Andrei Kudriavtsev und 17 weiteren Autor:innen. Beteiligte Einrichtung: IRCM, Montpellier Cancer Research Institute, INSERM U1194, Montpellier University, Montpellier, France. Hauptthemen laut MEDLINE: Neoplasm, Residual, Colonic Neoplasms, Circulating Tumor DNA. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ERA NET TRANSCAN Horizon 2020 Framework Program, Italian Ministry of Health, Fundación Científica Asociación Española Contra el Cancer (FC-AECC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Minimal residual disease (MRD) assessment using circulating nuclear DNA (cir‐nDNA) testing has demonstrated strong prognostic value in patients with operable stage III colon cancer (CC). However, further clinical research is needed to optimize the use of adjuvant therapy in this context. Since the sensitivity of variant allele frequency (VAF)‐based MRD detection depends on total cirDNA concentration, we investigated its variation in 67 stage III CC patients over 8 weeks following surgery. A majority of patients showed significantly higher post‐surgical cir‐nDNA levels compared to their pre‐surgical baseline—71.1% during the first month and 51.4% during the second. Cir‐nDNA levels tended to considerably vary (up to 18‐fold), especially during the first 3 weeks after surgery. We also observed a strong correlation between cir‐nDNA levels and neutrophil extracellular traps (NETs) markers throughout the 2‐month post‐operative period. While previous studies have generally assumed that cir‐nDNA levels decrease significantly within 1 month post‐surgery in MRD‐negative stage III patients, our findings challenge this paradigm. NETs appear to be a substantial source of cir‐nDNA and represent a major confounding factor in interpreting total cir‐nDNA, given the high inter‐individual variability in NETs production after surgery. Our data suggest that defining a single optimal time point for MRD testing may be misleading. Instead, we propose a sampling window between fourth and sixth week post‐surgery. Additionally, our results call into question the reliance on VAF as a standalone metric for MRD detection. The most robust strategy would involve integrated monitoring of total cir‐nDNA concentration, absolute mutant DNA levels, and NETs‐associated inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm, ResidualColonic NeoplasmsCirculating Tumor DNAHumansNeoplasm StagingFemaleMaleAgedMiddle AgedPrognosisBiomarkers, TumorExtracellular TrapsPostoperative PeriodReproducibility of ResultsAged, 80 and over

Stichwörter der Autor:innen

Neutrophil extracellular trapsadjuvant therapybiomarkerscirculating DNAcolorectal cancerdiagnosticminimal residual diseasepost‐surgery

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • IRCM, Montpellier Cancer Research Institute, INSERM U1194, Montpellier University, Montpellier, France.
  • Medical Oncology Department, Institut Català d'Oncologia (ICO)-IDIBELL, Barcelona, Spain.
  • Medical Oncology Department, VHIO Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Istituto di Candiolo, Fondazione del Piemonte per l'Oncologia-IRCCS, Candiolo, Torino, Italy.
  • ICM, Institut Régional du Cancer de Montpellier, Montpellier, France.
  • Faculty of Medicine and Health Sciences, Universitat de Barcelona CIBERONC, Barcelona, Spain.

ORCID-Profile: Andrei Kudriavtsev

Förderung

  • ERA NET TRANSCAN Horizon 2020 Framework Program
  • Italian Ministry of Health
  • Fundación Científica Asociación Española Contra el Cancer (FC-AECC)
  • RHU REVEAL
  • SIRIC
  • Société Française des Acides Nucleiques circulants (SFAC)
  • MSDAVENIR
  • Ministero della Salute

Zitieren

APA

Kudriavtsev, A., Daoud, S., Muñoz, C. I. C., Mirandola, A., Pisareva, E., Ruiz, J. G., Macagno, M., Gonzalez, N. S., Crapez, E., Ychou, M., Soler, R. S., Fenocchio, E., Calotti, P. X. F., Mazard, T., Vivas, C. S., Elez, E., Di Nicolantonio, F., & Thierry, A. R. (2026). Post‐surgery level of circulating DNA in stage III colon cancer patients: Impact on the reliability of minimal residual disease detection. International Journal of Cancer. https://doi.org/10.1002/ijc.70370

Vancouver

Kudriavtsev A, Daoud S, Muñoz CIC, Mirandola A, Pisareva E, Ruiz JG, et al. Post‐surgery level of circulating DNA in stage III colon cancer patients: Impact on the reliability of minimal residual disease detection. International Journal of Cancer. 2026. doi:10.1002/ijc.70370

BibTeX
@article{Kudriavtsev2026,
  author = {Kudriavtsev, Andrei and Daoud, Saidi and Muñoz, Catalina Isabel Cofre and Mirandola, Alexia and Pisareva, Ekaterina and Ruiz, Javier Gonzalo and Macagno, Marco and Gonzalez, Nadia Saoudi and Crapez, Evelyne and Ychou, Marc and Soler, Ramon Salazar and Fenocchio, Elisabetta and Calotti, Paula X Fernandez and Mazard, Thibault and Vivas, Cristina Santos and Elez, Elena and Di Nicolantonio, Federica and Thierry, Alain R},
  title = {Post‐surgery level of circulating DNA in stage III colon cancer patients: Impact on the reliability of minimal residual disease detection},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70370}
}
Kostenlos starten →